A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses

Gravitz, 2013, Cancer immunotherapy, Nature, 504, S1, 10.1038/504S1a Couzin-Frankel, 2013, Breakthrough of the year 2013. Cancer immunotherapy, Science, 342, 1432, 10.1126/science.342.6165.1432 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Ferris, 2016, Nivolumab for recurrent squamous-cell carcinoma of the head and neck, N Engl J Med, 375, 1856, 10.1056/NEJMoa1602252 Nghiem, 2016, PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma, N Engl J Med, 374, 2542, 10.1056/NEJMoa1603702 Migden, 2018, PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma, N Engl J Med, 379, 341, 10.1056/NEJMoa1805131 Socinski, 2018, Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC, N Engl J Med, 378, 2288, 10.1056/NEJMoa1716948 D'Angelo, 2018, Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic merkel cell carcinoma: a preplanned interim analysis of a clinical trial, JAMA Oncol, 4 Massard, 2016, Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer, J Clin Oncol, 34, 3119, 10.1200/JCO.2016.67.9761 Zhao, 2017, Intrinsic resistance of solid tumors to immune checkpoint blockade therapy, Cancer Res, 77, 817, 10.1158/0008-5472.CAN-16-2379 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 Turnis, 2015, Inhibitory receptors as targets for cancer immunotherapy, Eur J Immunol, 45, 1892, 10.1002/eji.201344413 Baumeister, 2016, Coinhibitory pathways in immunotherapy for cancer, Annu Rev Immunol, 34, 539, 10.1146/annurev-immunol-032414-112049 Anderson, 2016, Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation, Immunity, 44, 989, 10.1016/j.immuni.2016.05.001 Thommen, 2015, Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors, Cancer Immunol Res, 3, 1344, 10.1158/2326-6066.CIR-15-0097 Rotte, 2018, Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy, Ann Oncol, 29, 71, 10.1093/annonc/mdx686 Wierz, 2018, Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia, Blood, 131, 1617, 10.1182/blood-2017-06-792267 Harris-Bookman, 2018, Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma, Int J Cancer, 143, 3201, 10.1002/ijc.31661 Huard, 1997, Characterization of the major histocompatibility complex class II binding site on LAG-3 protein, Proc Natl Acad Sci U S A, 94, 5744, 10.1073/pnas.94.11.5744 Triebel, 1990, LAG-3, a novel lymphocyte activation gene closely related to CD4, J Exp Med, 171, 1393, 10.1084/jem.171.5.1393 Huard, 1994, Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes, Eur J Immunol, 24, 3216, 10.1002/eji.1830241246 Workman, 2004, Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo, J Immunol, 172, 5450, 10.4049/jimmunol.172.9.5450 Workman, 2005, Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223), J Immunol, 174, 688, 10.4049/jimmunol.174.2.688 Grosso, 2007, LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems, J Clin Investig, 117, 3383, 10.1172/JCI31184 Huang, 2004, Role of LAG-3 in regulatory T cells, Immunity, 21, 503, 10.1016/j.immuni.2004.08.010 Camisaschi, 2010, LAG-3 expression defines a subset of CD4+ CD25high Foxp3+ regulatory T cells that are expanded at tumor sites, J Immunol, 184, 6545, 10.4049/jimmunol.0903879 Baixeras, 1992, Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens, J Exp Med, 176, 327, 10.1084/jem.176.2.327 Andrews, 2017, LAG3 (CD223) as a cancer immunotherapy target, Immunol Rev, 276, 80, 10.1111/imr.12519 Ascierto, 2017, Ann Oncol, 28, 611, 10.1093/annonc/mdx440.011 Woo, 2012, Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape, Cancer Res, 72, 917, 10.1158/0008-5472.CAN-11-1620 Goding, 2013, Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma, J Immunol, 190, 4899, 10.4049/jimmunol.1300271 Matsuzaki, 2010, Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer, Proc Natl Acad Sci U S A, 107, 7875, 10.1073/pnas.1003345107 Sliwkowski, 2013, Antibody therapeutics in cancer, Science, 341, 1192, 10.1126/science.1241145 Wieder, 2018, Immune checkpoint blockade therapy, J Allergy Clin Immunol, 142, 1403, 10.1016/j.jaci.2018.02.042 Fosgerau, 2015, Peptide therapeutics: current status and future directions, Drug Discov Today, 20, 122, 10.1016/j.drudis.2014.10.003 Weinmann, 2016, Cancer immunotherapy: selected targets and small-molecule modulators, ChemMedChem, 11, 450, 10.1002/cmdc.201500566 Vlieghe, 2010, Synthetic therapeutic peptides: science and market, Drug Discov Today, 15, 40, 10.1016/j.drudis.2009.10.009 Vladimer, 2017, Global survey of the immunomodulatory potential of common drugs, Nat Chem Biol, 13, 681, 10.1038/nchembio.2360 Zhang, 2018, Structure reconstruction of LyP-1: Lc(LyP-1) coupling by amide bond inspires the brain metastatic tumor targeted drug delivery, Mol Pharm, 15, 430, 10.1021/acs.molpharmaceut.7b00801 Magiera-Mularz, 2017, Bioactive macrocyclic inhibitors of the PD-1/PD-L1 immune checkpoint, Angew Chem Int Ed Engl, 56, 13732, 10.1002/anie.201707707 Molek, 2011, Peptide phage display as a tool for drug discovery: targeting membrane receptors, Molecules, 16, 857, 10.3390/molecules16010857 Jerabek-Willemsen, 2014, MicroScale thermophoresis: interaction analysis and beyond, J Mol Struct, 1077, 101, 10.1016/j.molstruc.2014.03.009 Hmama, 1998, Attenuation of HLA-DR expression by mononuclear phagocytes infected with Mycobacterium tuberculosis is related to intracellular sequestration of immature class II heterodimers, J Immunol, 161, 4882, 10.4049/jimmunol.161.9.4882 He, 2016, Lymphocyte-activation gene-3, an important immune checkpoint in cancer, Cancer Sci, 107, 1193, 10.1111/cas.12986 Ascierto, 2017, Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy, J Clin Oncol, 35, 9520, 10.1200/JCO.2017.35.15_suppl.9520 Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954 Zhao, 2019, SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade, Acta Pharm Sin B, 9, 304, 10.1016/j.apsb.2018.08.009 Cook, 2016, LAG-3 confers a competitive disadvantage upon antiviral CD8+ T cell responses, J Immunol, 197, 119, 10.4049/jimmunol.1401594 Scala, 1998, Lymphocyte activation gene-3 (LAG-3) expression and IFN-γ production are variably coregulated in different human T lymphocyte subpopulations, J Immunol, 161, 489, 10.4049/jimmunol.161.1.489 Giraldo, 2015, Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer, Clin Cancer Res, 21, 3031, 10.1158/1078-0432.CCR-14-2926 Durham, 2014, Lymphocyte activation gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo, PLoS One, 9, 10.1371/journal.pone.0109080 Farsam, 2011, Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FOXP3+ Treg cells in vivo, Int Immunopharmacol, 11, 1802, 10.1016/j.intimp.2011.07.008 Betts, 2012, Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer, Gut, 61, 1163, 10.1136/gutjnl-2011-300970 Gagliani, 2013, Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells, Nat Med, 19, 739, 10.1038/nm.3179